company background image
ANNX logo

Annexon NasdaqGS:ANNX Stock Report

Last Price

US$7.38

Market Cap

US$779.7m

7D

17.3%

1Y

352.8%

Updated

13 Oct, 2024

Data

Company Financials +

ANNX Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

ANNX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Annexon, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Annexon
Historical stock prices
Current Share PriceUS$7.38
52 Week HighUS$8.40
52 Week LowUS$1.57
Beta1.28
11 Month Change2.50%
3 Month Change19.61%
1 Year Change352.76%
33 Year Change-66.45%
5 Year Changen/a
Change since IPO-58.45%

Recent News & Updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon: Unforced Error Sullies Prospects

Apr 03

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Nov 10
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Jul 25
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Feb 14
Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Dec 28
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

Shareholder Returns

ANNXUS BiotechsUS Market
7D17.3%1.2%1.0%
1Y352.8%21.2%33.7%

Return vs Industry: ANNX exceeded the US Biotechs industry which returned 21.2% over the past year.

Return vs Market: ANNX exceeded the US Market which returned 33.7% over the past year.

Price Volatility

Is ANNX's price volatile compared to industry and market?
ANNX volatility
ANNX Average Weekly Movement8.7%
Biotechs Industry Average Movement9.7%
Market Average Movement6.3%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ANNX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ANNX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201171Doug Lovewww.annexonbio.com

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.

Annexon, Inc. Fundamentals Summary

How do Annexon's earnings and revenue compare to its market cap?
ANNX fundamental statistics
Market capUS$779.73m
Earnings (TTM)-US$115.16m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANNX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$115.16m
Earnings-US$115.16m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.09
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ANNX perform over the long term?

See historical performance and comparison